logo
Plus   Neg
Share
Email

Japan's FTC Revokes Order, Finds Qualcomm Licensing Program Lawful

Qualcomm Inc (QCOM) said Friday that the Japan Fair Trade Commission or JFTC has reversed a 2009 cease-and-desist order affecting Qualcomm licensing in Japan.

Following a nine-year evidentiary proceeding, the JFTC concluded that Qualcomm's cross-licensing provisions and non-assertion covenants that were the subject of the cease-and-desist order did not violate Japanese antimonopoly law.

In 2010, the Tokyo High Court had issued a stay of the JFTC cease-and-desist order pending this proceeding. This week's JFTC decision, the result of a process that included 37 separate hearings, rejected an initial finding related to cross-license agreements between Qualcomm and Japanese manufacturers.

"We are very gratified to learn that after years of considering the evidence and applicable legal authority, the Japan Fair Trade Commission has concluded there was nothing improper about Qualcomm's cross-licensing program," said Don Rosenberg, general counsel and executive vice president of Qualcomm.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
AT&T Inc. (T) reported first-quarter adjusted earnings per share of $0.86 compared to $0.85, prior year. On average, 23 analysts polled by Thomson Reuters expected the company to report profit per share of $0.86 for the quarter. Analysts' estimates typically exclude special items. Adjusting for amortization,... Shares of Credit Suisse Group AG were gaining around 3 percent in Swiss trading after the banking major reported Wednesday higher profit in its first quarter, despite weak revenues. Looking ahead, the company said it is cautiously optimistic about its prospects for the second quarter of 2019. The company remains focused on increasing its returns over the course of 2019 and beyond. While reporting financial results for the first quarter, Thermo Fisher Scientific Inc. (TMO) on Wednesday raised its adjusted earnings and revenue guidance for the full year 2019 to reflect strong operational performance and the acquisition of Brammer Bio, partially offset by a more adverse foreign exchange...
Follow RTT